Last reviewed · How we verify
NCT06084377
Isolation of Cell Free Fetal DNA From Spent Culture Medium and Its Potential Role for Preimplantation Genetic Diagnosis (PGD).
trial testing Preimplantation Genetic Screening in Females Undergoing PGD Technology for Medical Conditions in 27 participants. Completed in 23 September 2023.
5 April 2023
Quick facts
| Lead sponsor | Damascus University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 27 |
| Start date | 18 May 2020 |
| Primary completion | 5 April 2023 |
| Estimated completion | 23 September 2023 |
| Sites | 1 location across Syria |
Drugs / interventions tested
- Preimplantation Genetic Screening
Conditions studied
- Females Undergoing PGD Technology for Medical Conditions — all drugs for Females Undergoing PGD Technology for Medical Conditions →
Sponsor
Damascus University
Who can join
Adults 22 to 44, female only, with Females Undergoing PGD Technology for Medical Conditions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Preimplantation genetic testing for chromosomal screening is, at present, the most reliable method to assess the genetic status of preimplantation embryos. DNA isolated and amplified from trophectoderm (TE) biopsiesis the method currently used for preimplantation genetic testing, but it has significant limitations. There is increasing evidence for a ''true'' noninvasive approach consisting of the analysis of cell-free DNA (cfDNA) released by the embryo into the spent blastocyst medium (SBM) during the late stages of preimplantation development. This study is to assess whether Noninvasive prenatal genetic diagnosis using cell-free fetal DNA in spent culture medium will substitute for trophectoderm biopsy for heritable disorders screening and if it represents the total fetal genomic DNA. A total of 27 spent blastocyst media (SBM) from women undergoing IVF will be enrolled with agesless than44 years, whose indications for preimplantation genetic diagnosis for Euploid/Aneuploid embryo determination, were advanced maternal age, recurrent miscarriage, or recurrent implantation failure.We examined the presence of the cell free DNA in spent culture media and whether this DNA is reliable and can be representative of the chromosomal constitution of a blastocyst. So we can affirm that Noninvasive prenatal determination of fetal sex using cell-free fetal DNA (used here as a marker) provides an alternative to invasive techniques for some heritable disorders.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06084377
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Preimplantation Genetic Screening
Trials testing the same drug.
- NCT03173885 — Investigating the Cryopreserved Blastocyst's ImplantatiOn Potential After Genetic Screening · NA · terminated
Other Damascus University trials
Trials by the same sponsor.
- NCT07532161 — Comparison Between Liquid Fibrin and Soft Laser Effects on Healing and Relapse After Lip Repositioning Surgery · NA · not yet recruiting
- NCT07515612 — The Impact of Valerian and Chamomile on Children's Anxiety in the Dental Clinic. · NA · recruiting
- NCT07272798 — Cardiac Self-Efficacy in Patients With Chronic Thromboembolic Pulmonary Hypertension · recruiting
- NCT07426523 — Effectiveness of Needle-Free Infiltration Anesthesia in Reduction of Dental Pain and Anxiety During Local Anesthesia. · NA · completed
- NCT07366788 — Clinical Outcomes of Mandibular Primary Molar Extraction Using Physics Forceps in Children · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06084377 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Damascus University
- Last refreshed: 18 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06084377.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing